Vaginal Erbium Laser: the second generation thermotherapy for the genitourinary syndrome of menopause (GSM). A pilot study

Gambacciani, Marco; Levancini, Marco

doi:10.1016/j.maturitas.2015.02.105

Cited by 14 publications

(25 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ten studies included breast cancer survivors. [43][44][45][46][47][48][49][50][51][52] Below, we discuss the studies in terms of the therapeutic modality used. We present the results in terms of histological changes, physician assessment, subjective patient reports, adverse events, author recommendations and long-term outcomes.…”

Section: Resultsmentioning

confidence: 99%

“…There are 11 published case series with 692 patients detailing the use of this laser in the management of VVA/GSM (Table ). Three studies included women with a history of breast cancer …”

Section: Discussionmentioning

confidence: 99%

“…Three studies included women with a history of breast cancer. 43,46,51 Histological changes Gaspar et al 42 investigated six patients who received Er:YAG laser concurrently with estriol ovules. Vaginal biopsies were performed at baseline, 1, 3, 6 and 12 months post-treatment.…”

Section: Erbium:yag Lasermentioning

confidence: 99%

See 2 more Smart Citations

Review of non‐invasive vulvovaginal rejuvenation

Photiou

Lin

Dubin

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Vulvovaginal atrophy (VVA) or genitourinary syndrome of menopause (GSM) may affect up to 90% of menopausal women. Features include vulvovaginal atrophy, vulvovaginal laxity, vulvovaginal dryness and irritation, dyspareunia, anorgasmia and urinary symptoms. The vulva, vagina and bladder are oestrogen‐responsive tissues, but oestrogen replacement therapy is not possible in women who have hormone‐responsive cancers or normal oestrogen levels. Therefore, there is a role for alternative treatments. To date, three non‐surgical energy‐based therapies have been proposed: fractional microablative CO2 laser, erbium:YAG laser and temperature‐controlled radiofrequency (RF). Our objective was to assess the available evidence for the safety and efficacy of erbium:YAG laser, microablative fractional CO2 laser and RF in the treatment of VVA/GSM. The authors reviewed the current published literature evaluating these therapies. All three therapies appear safe; however, all the studies were uncontrolled and used different protocols and outcome measurements. Therefore, comparison of treatments is difficult. It appears that there is more evidence in favour of the CO2 laser than the erbium:YAG laser. Both lasers have more evidence than RF. In conclusion, microablative CO2 laser, erbium:YAG laser and RF may be offered to patients suffering from VVA/GSM as an alternative or adjunct to conventional therapies. Further well‐conducted controlled studies are needed.

show abstract

Section: Resultsmentioning

confidence: 99%

“…There are 11 published case series with 692 patients detailing the use of this laser in the management of VVA/GSM (Table ). Three studies included women with a history of breast cancer …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Review of non‐invasive vulvovaginal rejuvenation

Photiou

Lin

Dubin

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Further high-quality studies are currently being undertaken. In some women for whom estrogen is contraindicated, vaginal laser treatment may have a definite role; several small studies have demonstrated efficacy in breast cancer survivors, [10][11][12][13][14][15] but the quality of the evidence remains poor.…”

Section: Genitourinary Syndrome Of the Menopausementioning

confidence: 99%

Energy devices in vaginal therapy

Hillard

2019

The Obstetric & Gynaecologis

View full text Add to dashboard Cite

“…22 This was followed by a recent pilot study, which showed that erbium laser is an effective treatment for VVA in breast cancer survivors. 23 Several prospective observational trials with both CO 2 and erbium lasers have yielded encouraging findings; however, the results of randomised controlled trials with a sham laser control are still awaited. 24,25 Local and systemic hormone replacement therapy Treatment is indicated in menopausal women and women with premature ovarian insufficiency who are symptomatic of VVA.…”

Section: Vaginal Laser Treatmentmentioning

confidence: 99%

Vaginal estrogen deficiency

Khanjani

Panay

2019

The Obstetric & Gynaecologis

View full text Add to dashboard Cite

Key content Vaginal estrogen deficiency occurs with declining serum estradiol levels in menopause and premature ovarian insufficiency. The symptoms most commonly involve vulval and vaginal dryness, pruritis, dyspareunia and discharge. Treatment is simple and easily accessible and can be hormonal and nonhormonal. Nonhormonal treatments are particularly helpful for women who cannot take estrogen. They include simple treatments such as local lubricants and moisturisers, and newer modalities of treatment, including laser. Vaginal estrogen is the most commonly used form of hormonal treatment. However, selective estrogen receptor modulators, tissue‐selective estrogen complexes, androgens and dehydroepiandrosterone have recently been introduced and are effective and safe. Learning objectives To understand the pathogenesis, symptoms and diagnosis of vulvovaginal atrophy. To appreciate attitudes and stances towards vulvovaginal atrophy. To understand management options for vaginal estrogen deficiency. Ethical issues The impact of vulvovaginal atrophy on the quality of life of many women is profound but underestimated. Vulvovaginal atrophy is underdiagnosed and undertreated. Considering that more women are spending a significant proportion of their lives in the postmenopausal period, understanding the diagnosis and treatment of vulvovaginal atrophy must develop in synchrony with this growing unmet need.

show abstract

Vaginal Erbium Laser: the second generation thermotherapy for the genitourinary syndrome of menopause (GSM). A pilot study

Cited by 14 publications

References 0 publications

Review of non‐invasive vulvovaginal rejuvenation

Review of non‐invasive vulvovaginal rejuvenation

Energy devices in vaginal therapy

Vaginal estrogen deficiency

Contact Info

Product

Resources

About